Zeta Surgical gets FDA clearance for its TMS robotic system

Zeta Surgical has received FDA 510(k) clearance for its TMS Robotic System, classified as a stereotaxic instrument. The clearance means the company can now commercially deploy a robotic platform designed to position and adjust TMS coils automatically during treatment sessions, with sub-millimeter accuracy.

Transcranial magnetic stimulation is a non-invasive therapy that uses magnetic fields to stimulate specific brain regions. It is primarily used for treatment-resistant depression, but clinicians also apply it to obsessive-compulsive disorder, PTSD, and addiction disorders. Getting the coil in exactly the right spot, and keeping it there, is essential for the therapy to work. That is the problem Zeta's robotic system is built to solve.

The company says setup takes under a minute and the system can be used in virtually any clinical setting, not just specialized facilities. The platform tracks patient movement in real time and adjusts the coil position automatically to keep stimulation on target throughout the session.

How does it work?

The TMS Robotic System builds on Zeta's existing navigation technology, which already received FDA clearance in October 2025. Rather than relying on a clinician to manually position and hold a TMS coil, the robotic system takes over that job mechanically and dynamically.

• Real-time image guidance tracks the patient's head position continuously
• If the patient moves, the system automatically repositions the coil to compensate
• Targeting accuracy is at the sub-millimeter level, comparable to what you'd expect in an operating room
• Setup takes less than a minute and works across different clinical environments

Benjamin Lee, chief product officer at Zeta Surgical, said the system uses the same guidance technology already trusted in the company's TMS deployments. "It uses that same guidance to dynamically adjust position throughout a session, without asking clinics to change how they already work," he said.

Why does it matter?

TMS works only when the magnetic coil is hitting the right target in the brain. In practice, patients move during sessions, and manual repositioning is imprecise. That inconsistency can reduce how well the therapy works and makes it harder to replicate results across sessions or between clinics.

A robotic system that handles positioning automatically could make TMS more reliable and easier to deliver at scale. Dr. William Gormley, co-founder of Zeta Surgical and a neurosurgeon at Mass General Brigham, put it plainly: "This clearance brings operating-room-level navigation and robotic accuracy into a platform that can be rapidly deployed in virtually any clinic."

That matters because access to TMS is currently limited. The therapy requires trained staff and specialized equipment, and availability is concentrated in larger medical centers. A system that is faster to set up and easier to use in a standard clinic could help more patients get consistent, targeted treatment.

The context

This clearance is the latest in a string of regulatory wins for Zeta Surgical. The company has collected FDA clearances across several of its technologies over the past year, including:

• The TMS navigation system (October 2025)
• Expanded software functionality
• Mixed reality technology
• AI-powered navigation capabilities
• Its navigated Stylet and Bolt instruments

In May 2026, the company also reported the first commercial deployment of its TMS navigation system. The robotic system clearance follows that milestone and adds a new layer of automation on top of the navigation platform already in the field.

The broader trend here is the push to bring surgical-grade precision tools into outpatient and general clinical settings. Neuromodulation therapies like TMS are gaining ground as mental health care looks for treatments that work for patients who do not respond to medication. Making those therapies more accurate and easier to deliver consistently is a real clinical need, and regulators appear willing to clear technology that addresses it.